For Doctors in a Hurry
- Researchers investigated how the coexistence of multiple chronic conditions, known as multimorbidity, relates to cognitive decline and specific Alzheimer disease biomarkers.
- This cross-sectional study analyzed 3,808 dementia-free participants with a mean age of 64.9 years to evaluate multimorbidity and neurological health.
- Higher multimorbidity burden significantly correlated with increased amyloid deposition, elevated phosphorylated tau 217, and greater white matter hyperintensity volume.
- The authors concluded that chronic disease accumulation is linked to accelerated neurodegeneration and cerebral small vessel disease in asymptomatic adults.
- Clinicians should prioritize holistic management of chronic conditions to potentially mitigate brain pathology and delay the onset of cognitive impairment.
The Neurological Toll of Cumulative Chronic Disease
As the global population ages, the clinical reality of multimorbidity, defined as the coexistence of two or more chronic conditions, has become the rule rather than the exception in primary and specialty care [1, 2]. While clinicians have long observed that patients with complex medical histories face a higher risk of functional decline, the specific pathways linking systemic health to neurodegenerative processes remain poorly defined [3, 4]. Current evidence suggests that physical and psychological comorbidities can more than double the risk of developing clinical dementia, yet most disease-modifying trials for Alzheimer's disease continue to exclude these complex patients [5, 6]. This gap in external validity leaves practitioners with limited data on how common ailments like hypertension or diabetes interact with the underlying proteopathy of cognitive decline [7]. A recent large-scale analysis now examines these mechanistic links by evaluating how total chronic disease burden correlates with specific biomarkers of neurodegeneration and vascular injury.
Quantifying the Burden in a Diverse Cohort
The researchers conducted a cross-sectional analysis of 3,808 dementia-free participants enrolled in the Health and Aging Brain Study: Health Disparities. This large-scale cohort provided a robust sample for examining the intersection of systemic health and neurology, featuring a study population with a mean age of 64.9 ± 8.5 years. Notably, 62 percent of the participants were female, reflecting a demographic often disproportionately affected by both multimorbidity and Alzheimer's disease. By focusing on individuals without clinical dementia, the study aimed to identify pathological changes occurring in the preclinical phase, a window where preventive therapeutic interventions are most likely to succeed. To capture the true complexity of patient health, the authors assessed multimorbidity burden using a latent construct (a statistical method that infers a single underlying severity score from multiple observed variables). This construct synthesized data from objective clinical measures, formal medical history, and patient self-reports to create a comprehensive profile of each participant's physiological strain. This approach allowed the team to move beyond simple disease counts and instead quantify the cumulative impact of various chronic ailments on the brain. Cognitive performance was evaluated with equal rigor through the estimation of a latent factor score for cognition. This score was derived using confirmatory factor analysis, a statistical technique that verifies the relationship between observed test scores and an underlying cognitive ability, alongside a battery of standardized neuropsychological tests. By utilizing these modeling techniques, the researchers were able to correlate the cumulative burden of chronic disease with specific deficits in cognitive domains and biological markers of neurodegeneration. For practicing physicians, this means that a patient's overall medical complexity can serve as a direct, measurable proxy for their neurological vulnerability.
Mapping Systemic Health to Molecular Pathology
To delineate the relationship between systemic health and neurological decline, the researchers used linear and logistic regression to examine associations between multimorbidity and specific biomarkers. This framework allowed the team to determine how the cumulative weight of chronic conditions influences distinct pathological pathways in the brain. The investigation focused heavily on established Alzheimer's disease biomarkers, including positron emission tomography (PET) amyloid standardized uptake value ratios and positivity, which provide a quantitative measure of amyloid plaque density. Additionally, the authors analyzed fluid-based indicators, specifically plasma β-amyloid 42/40 and phosphorylated tau (p-tau181 and p-tau217) measures, to capture the molecular signatures of proteinopathy in the blood. The analysis revealed that a greater multimorbidity burden was associated with higher PET amyloid standardized uptake value ratios and positivity. This indicates that patients managing multiple chronic conditions are more likely to harbor significant amyloid deposition even before cognitive symptoms manifest. Furthermore, the study found that a greater multimorbidity burden was associated with elevated p-tau181 and p-tau217, which are specific markers of tau phosphorylation and neurofibrillary tangle pathology. For clinicians, these findings suggest that the physiological stress of comorbid diseases may actively accelerate the core pathological processes of Alzheimer's disease, providing a measurable link between systemic physical health and the molecular environment of the aging brain.
Structural Brain Changes and Vascular Injury
The study evaluated neurodegeneration through several specific biomarkers, including cortical thickness (a measure of the brain's outer layer of gray matter) and hippocampal volume (the size of the brain region primarily responsible for memory formation). Additionally, the researchers measured plasma neurofilament light, a structural protein released into the blood when axons are damaged, and total tau, a marker of general neuronal injury. The analysis of the 3,808 participants demonstrated that a greater multimorbidity burden was associated with reduced cortical thickness and hippocampal volume. This suggests that the cumulative effect of chronic diseases may accelerate the physical atrophy of brain structures essential for daily cognitive function. Furthermore, the data showed that a greater multimorbidity burden was associated with elevated neurofilament light and total tau, providing biochemical evidence of ongoing neuronal and axonal damage in individuals with complex medical histories. Beyond direct neurodegeneration, the researchers investigated the impact of chronic disease on the brain's vasculature. Cerebral small vessel disease biomarkers included magnetic resonance imaging (MRI) white matter hyperintensities (areas of increased signal indicating damage to the brain's deep wiring), as well as cerebral microbleeds and lacunes (small, deep strokes caused by the occlusion of a single penetrating artery). The findings indicated that a greater multimorbidity burden was associated with increased white matter hyperintensity volume, reflecting a higher degree of chronic ischemic injury. Additionally, the study found that a greater multimorbidity burden was associated with the presence of lacunes and cerebral microbleeds. For primary care providers and neurologists, these results highlight that systemic multimorbidity does not just influence Alzheimer's pathology but also drives significant vascular injury, contributing to a multifaceted profile of brain damage that complicates patient prognosis.
Clinical Implications for Preventive Care
The analysis of 3,808 dementia-free participants, who had a mean age of 64.9 years (standard deviation 8.5) and were 62 percent female, demonstrates that the cumulative impact of chronic health conditions has a measurable effect on mental function long before clinical dementia is diagnosed. Using a latent factor score for cognition (a statistical value representing overall cognitive performance derived from multiple neuropsychological tests), the researchers determined that a greater multimorbidity burden was associated with worse cognition. This finding suggests that the presence of multiple chronic diseases, identified through medical history and objective measures, serves as a significant indicator of diminished cognitive reserve even in patients who do not yet meet the criteria for cognitive impairment. These cognitive deficits are linked to a broad spectrum of underlying pathologies. The study found that a higher burden of chronic disease correlated with increased positron emission tomography (PET) amyloid standardized uptake value ratios, which quantify the density of amyloid plaques in the brain, as well as higher levels of plasma p-tau181 and p-tau217. Furthermore, the data linked multimorbidity to markers of neurodegeneration, such as elevated plasma neurofilament light and total tau, alongside structural changes including reduced hippocampal volume and cortical thickness. The presence of cerebral small vessel disease, evidenced by white matter hyperintensity volume and the presence of lacunes and cerebral microbleeds, further characterizes the complex brain environment in these patients. For the practicing clinician, these findings underscore the necessity of a holistic approach to patient care that extends beyond the siloed management of individual diseases. Because a greater multimorbidity burden was associated with worse cognition and a higher load of Alzheimer's and vascular biomarkers, aggressively managing the total burden of chronic conditions offers a tangible strategy to reduce overall pathophysiological damage. By addressing the cumulative effect of systemic health issues in primary care settings, physicians have a critical opportunity to delay the onset of cognitive decline and mitigate the progression of neurodegenerative pathology in aging populations.
References
1. Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018. doi:10.1016/s0140-6736(18)32203-7
2. Ferrari AJ, Santomauro D, Aali A, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024. doi:10.1016/s0140-6736(24)00757-8
3. Valletta M, Canevelli M, Gasparini F, et al. Multimorbidity and fluid biomarkers of Alzheimer's disease: a systematic review.. European geriatric medicine. 2025. doi:10.1007/s41999-025-01222-y
4. Hill NL, Bhargava S, Brown MJ, et al. Cognitive complaints in age-related chronic conditions: A systematic review.. PloS one. 2021. doi:10.1371/journal.pone.0253795
5. Canevelli M, Ancidoni A, Valletta M, et al. Reporting of comorbidities and health status of participants in clinical trials testing amyloid- and tau-targeting monoclonal antibodies for Alzheimer's disease: A systematic review.. Journal of Alzheimer's disease : JAD. 2024. doi:10.1177/13872877241289549
6. Du M, Liu M, Liu J. Effects of physical and psychological multimorbidity on the risk of dementia: multinational prospective cohorts and a meta-analysis.. BMC medicine. 2024. doi:10.1186/s12916-024-03642-2
7. Shepherd H, Livingston G, Chan J, Sommerlad A. Hospitalisation rates and predictors in people with dementia: a systematic review and meta-analysis. BMC Medicine. 2019. doi:10.1186/s12916-019-1369-7
